HONG KONG – China's Frontier Biotechnologies Co. Ltd. achieved positive results in a phase III study for the world's first injectable long-acting HIV drug. The weekly dose drug is targeted at Chinese patients via local development and manufacturing. Read More

HONG KONG – Although the government has set its sights on advancing personalized medicine in China, most of the existing gene-related technologies are still of foreign origin, so are some of the leading companies operating here. The question at the moment is whether development of precision medicine in the country is a domestic or foreign affair? And where will the huge amount of government funding in the space go? Read More

HONG KONG – Swiss pharmaceutical giant Novartis AG has officially launched its third global R&D hub, this one in China, where spirited debate over whether the country has true innovation or not is a daily occurrence. Read More

HONG KONG – The findings of a new collaborative study by Chinese and German scientists suggest that activation in mice of a specific type of immune response, known as a Type 2 (Th2) response, using parasitic worm-derived stimuli, could clear the way to the development of new treatments for rheumatoid arthritis (RA). Read More

Adocia SAS, of Lyon, Franc, and Eli Lilly and Co., of Indianapolis, reported top-line results from a phase I trial testing Biochaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly and developed using Adocia's technology. Read More